Hongwei Yao | Gastrointestinal Pharmacology | Best Researcher Award

Prof. Hongwei Yao, capital medical university Affiliated Beijing Friendship Hospital, China

Prof. Dr. Hongwei Yao 🧑‍⚕️ is a renowned gastrointestinal surgeon with over 20 years of experience in diagnosing and treating GI tumors. 💉 He excels in laparoscopic and transanal endoscopic microsurgery (TEM) 🩺 and has led multiple research studies, authoring 100+ academic papers 📚—90+ focused on colorectal surgery. 🧬 He is the lead translator of Standard Laparoscopic Surgery for Upper GI Tract and co-translator of the national textbook Colorectal and Anal Surgery. 🔬 Prof. Yao holds two utility model patents for surgical innovations and continues to pioneer breakthroughs in colorectal cancer treatment. 🧠 His work bridges clinical expertise and cutting-edge research.

Publication Profile

Orcid

Education

Prof. Dr. Hongwei Yao 🧑‍⚕️ is a distinguished gastrointestinal surgeon with over 20 years of clinical excellence in diagnosing and treating GI tumors 🧬. An expert in advanced surgical techniques such as laparoscopic surgery and transanal endoscopic microsurgery (TEM) 🔍, he is known for handling complex gastrointestinal procedures with precision. He has led numerous research projects and authored more than 100 academic papers 📚, with over 90 focusing on colorectal surgery. He served as lead translator of Standard Laparoscopic Surgery for Upper GI Tract 📘 and co-translator of Colorectal and Anal Surgery 📖. Prof. Yao also holds two utility model patents .

Editorial Appointments

Prof. Hongwei Yao 🧑‍⚕️ holds esteemed editorial roles in several leading medical journals. Since December 2019, he has served as Associate Editor for the Diseases of the Colon & Rectum journal 🧻, which is indexed in SSCI. Additionally, he has been a dedicated Editorial Board Member for the Chinese Journal of Inflammatory Bowel Diseases 💢 since February 2017, and for the Chinese Journal of Digestive Surgery 🩺 since July 2021, both indexed in CSCD and CSTPCD. These appointments reflect his profound expertise in gastrointestinal surgery and commitment to advancing medical research and literature 📚.

Research Focus

Prof. Hongwei Yao 🧑‍⚕️ focuses his groundbreaking research on colorectal cancer, gastrointestinal surgery, and translational oncology 🧬. His core interest lies in neoadjuvant therapies combining chemoradiation with immunotherapy (especially PD-1/PD-L1 blockade) for treating locally advanced rectal cancer 🎯. His innovative studies explore gut microbiota, nanomedicine, biospectroscopy, and surgical optimization to personalize cancer care 🧪. He also advances wound healing and stem cell therapies for post-surgical recovery 🩹. Through high-impact publications and clinical trials, Prof. Yao contributes to redefining standards in cancer diagnostics, surgical margins, and immune modulation in GI tumors ⚕️.

Publication Top Notes

Neoadjuvant chemoradiation with or without PD-1 blockade in locally advanced rectal cancer: a randomized phase 2 trial

Opportunities and challenges of indocyanine green in gastrointestinal cancers for intraoperative and nano-medicine application

Opportunities and challenges of nanomaterials in wound healing: Advances, mechanisms, and perspectives

Enhancing thromboprophylaxis after colorectal cancer surgery in China: Bridging the gap between evidence and implementation through pathway optimization

Exploring causal correlations between circulating levels of cytokines and colorectal cancer risk: A Mendelian randomization analysis

Gut microbiome model predicts response to neoadjuvant immunotherapy plus chemoradiotherapy in rectal cancer

Definition and grading of anastomotic leakage following right hemicolectomy

Perfusion outcomes with near-infrared indocyanine green imaging system in laparoscopic total mesorectal excision for mid-rectal or low-rectal cancer (POSTER): a study protocol

The Role and Prospects of Mesenchymal Stem Cells in Skin Repair and Regeneration

Mifleh Tatour | Gastrointestinal Pharmacology | Best Researcher Award

Dr. Mifleh Tatour, Clalit Health Services, Israel

Dr. Mifleh Tatour (b. 1989, Israel) is a distinguished physician and researcher specializing in family medicine and hematology. He earned his M.D. from the Technion – Israel Institute of Technology and holds an M.Sc. in Hematology and Cancer. A prolific researcher, he has published extensively on autoimmune hepatitis and heparanase activity. Currently, he serves as a family medicine resident at Clalit Health Services and a lecturer at Bar-Ilan University. Passionate about medical education, he mentors aspiring physicians. Fluent in Hebrew and Arabic, Dr. Tatour is committed to advancing healthcare and medical training. 🏥🔬

Publication Profile

orcid

Education

Dr. Mifleh Tatour 🎓 is a distinguished medical professional with a strong background in hematology, cancer research, and hepatology. He earned his B.Sc. (Cum Laude) in Medical Laboratory Sciences (2008-2012) and an M.Sc. (Cum Laude) in Hematology and Cancer (2013-2015) from the Technion – Israel Institute of Technology 🏥. He later completed his M.D. (2014-2019) at the same institution. Dr. Tatour has contributed to multiple high-impact publications, including studies on autoimmune hepatitis and heparanase activity. In 2024, he was accepted into the prestigious “Northern Stars” program 🌟 at Bar-Ilan University. His research continues to shape the future of hepatology and oncology.

Work Experience

Dr. Mifleh Tatour 🩺 is an accomplished medical educator and family medicine specialist. Since 2021, he has been a Family Medicine Resident at Clalit Health Services – Northern District, while also serving as a lecturer and instructor at Bar-Ilan University’s Faculty of Medicine 🎓. He directs the “Bread and Butter” course for first-year residents and mentors students in various programs. Previously, he worked at Emek Medical Center and Carmel Medical Center. Passionate about education, he has trained students in hematology, psychometrics, and medical school preparation 📚. His dedication to teaching and mentoring continues to shape future healthcare professionals.

Clinical Impact

Dr. Mifleh Tatour 🏥 is a dedicated Family Medicine Resident at Clalit Health Services, seamlessly integrating clinical practice, research, and education. With experience as a physician assistant, internal medicine instructor, and hematology lab instructor, he has developed a comprehensive medical expertise 🩺. His commitment to patient care is complemented by his passion for teaching, mentoring future doctors, and advancing medical knowledge 📚. Through his roles in academia and clinical settings, Dr. Tatour continues to make a significant impact on healthcare, ensuring high-quality treatment while shaping the next generation of physicians 👨‍⚕️.

Research Focus

Dr. Mifleh Tatour’s research primarily focuses on the intersection of autoimmune diseases 🦠 and hematological malignancies 🧬, particularly the increased risk of Non-Hodgkin Lymphoma (NHL) in patients with Autoimmune Hepatitis (AIH) 🏥. His work involves large-scale retrospective cohort studies 📊 to identify potential pathophysiological links 🔬 between chronic liver inflammation and lymphoproliferative disorders. His research aims to improve early detection 🛑 and risk assessment ⚠️ for AIH patients susceptible to lymphoma, contributing to personalized medicine 🏥 and better clinical outcomes 📈. His work is significant in the fields of gastroenterology, immunology, and oncology 🩺.

Publication Top Notes

Increased Risk of Non-Hodgkin Lymphoma in Autoimmune Hepatitis: A Large Retrospective Cohort Study